Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Ernexa Therapeutics Inc. (ERNA) had Consolidated Net Income/Loss of $-8.20M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-8.20M |
|
-- |
|
-- |
|
$2.73M |
|
$-2.73M |
|
$-5.46M |
|
$-8.19M |
|
$-8.19M |
|
$-8.20M |
|
$-8.20M |
|
|
Consolidated Net Income/Loss |
$-8.20M |
$-8.20M |
|
$-2.73M |
|
$-2.66M |
|
53.36M |
|
53.36M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$2.21M |
|
$0.07M |
|
$2.85M |
|
$5.06M |
|
$10.44M |
|
-- |
|
$0.57M |
|
$11.01M |
|
$-5.95M |
|
$-7.99M |
|
$-5.95M |
|
52.25M |
|
| Cash Flow Statement Financials | |
$-2.06M |
|
-- |
|
$2.25M |
|
$1.73M |
|
$1.92M |
|
$0.19M |
|
$0.50M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.21 |
|
-- |
|
-- |
|
-- |
|
-0.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
137.83% |
|
102.60% |
|
-162.13% |
|
137.85% |
|
$-0.11 |
|
$-0.04 |
|
$-0.04 |
|